A recent decision by the Food and Drug Administration will allow Keryx Biopharmaceuticals to overcome a large obstacle in the manufacturing of its kidney drug Auryxia, according to the Boston Business Journal.
In August, the Boston-based drugmaker stopped manufacturing Auryxia due to issues with its manufacturer over converting active pharmaceutical ingredients into finished pills.
On Wednesday, the FDA approved the use of a second manufacturer, allowing Keryx to reinitiate manufacturing processes and supply the drug to wholesalers.
"Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients," said Keryx CEO Greg Madison in a statement.
More articles on supply chain:
FDA may allow medical companies to promote drugs, devices for off-label uses
J.B. Hunt to add hundreds of trucks next year despite industry slowdown: 3 takeaways
Global supply chain risk index on the rise: 4 things to know